Brainstorm Cell Therapeutics Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Brainstorm Cell Therapeutics stock.
View analyst ratings for Brainstorm Cell Therapeutics or view top-rated stocks.

Wall Street analysts have given Brainstorm Cell Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Brainstorm Cell Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Brainstorm Cell Therapeutics saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 1,040,000 shares, an increase of 16.3% from the July 29th total of 894,200 shares. Based on an average trading volume of 298,600 shares, the short-interest ratio is currently 3.5 days. Approximately 3.5% of the shares of the company are sold short.
View Brainstorm Cell Therapeutics' Short Interest.

Brainstorm Cell Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 21st 2021.
View our earnings forecast for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings data on Thursday, August, 5th. The biotechnology company reported ($0.17) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.07.
View Brainstorm Cell Therapeutics' earnings history.

Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BCLI stock has decreased by 47.2% and is now trading at $3.53.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued 12-month price objectives for Brainstorm Cell Therapeutics' shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Brainstorm Cell Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 239.9% from the stock's current price.
View analysts' price targets for Brainstorm Cell Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Brainstorm Cell Therapeutics include Poseida Therapeutics (PSTX), Autolus Therapeutics (AUTL), Tarsus Pharmaceuticals (TARS), Ikena Oncology (IKNA), Compugen (CGEN), Innate Pharma (IPHA), Codiak BioSciences (CDAK), Lineage Cell Therapeutics (LCTX), SQZ Biotechnologies (SQZ), Outlook Therapeutics (OTLK), Jounce Therapeutics (JNCE), Fusion Pharmaceuticals (FUSN), Athira Pharma (ATHA), Orchard Therapeutics (ORTX) and Oyster Point Pharma (OYST).
View all of BCLI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Isoray (ISR), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."

Brainstorm Cell Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.89%), JPMorgan Chase & Co. (1.92%), BlackRock Inc. (1.31%), Susquehanna International Group LLP (0.00%), Millennium Management LLC (1.02%) and Geode Capital Management LLC (0.73%). Company insiders that own Brainstorm Cell Therapeutics stock include David Setboun, International Holdings Ltd Acc, Preetam Shah, Ralph Dr Kern and Sankesh Abbhi.
View institutional ownership trends for Brainstorm Cell Therapeutics.

BCLI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, JPMorgan Chase & Co., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Brainstorm Cell Therapeutics or view top insider-selling stocks.

BCLI stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ergoteles LLC, Simplex Trading LLC, Tibra Equities Europe Ltd, Vanguard Group Inc., Renaissance Technologies LLC, GSA Capital Partners LLP, and Goldman Sachs Group Inc.. Company insiders that have bought Brainstorm Cell Therapeutics stock in the last two years include David Setboun, Preetam Shah, Ralph Dr Kern, and Sankesh Abbhi.
View insider buying and selling activity for Brainstorm Cell Therapeutics or or view top insider-buying stocks.

Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCLI stock can currently be purchased for approximately $3.53.

Brainstorm Cell Therapeutics has a market capitalization of $128.21 million. The biotechnology company earns $-31,810,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis.

Brainstorm Cell Therapeutics employs 40 workers across the globe.

The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com.

Brainstorm Cell Therapeutics is headquartered at 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019.

Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at (201) 488-0460 or via email at [email protected].